These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 15518071

  • 1. [The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes].
    Cecha J, Drabek G, Błazelonis A, Romanowski W, Zubelewicz-Szkodzińska B.
    Wiad Lek; 2004; 57(5-6):255-8. PubMed ID: 15518071
    [Abstract] [Full Text] [Related]

  • 2. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR, Kanwar YS.
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [Abstract] [Full Text] [Related]

  • 3. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress.
    Mason RP, Walter MF, Jacob RF.
    Circulation; 2004 Jun 01; 109(21 Suppl 1):II34-41. PubMed ID: 15173061
    [Abstract] [Full Text] [Related]

  • 4. Antioxidative effects of statins.
    Adam O, Laufs U.
    Arch Toxicol; 2008 Dec 01; 82(12):885-92. PubMed ID: 18670762
    [Abstract] [Full Text] [Related]

  • 5. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
    Mason RP, Walter MF, Day CA, Jacob RF.
    Am J Cardiol; 2005 Sep 05; 96(5A):11F-23F. PubMed ID: 16126019
    [Abstract] [Full Text] [Related]

  • 6. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
    Ito MK, Talbert RL, Tsimikas S.
    Pharmacotherapy; 2006 Jul 05; 26(7 Pt 2):85S-97S; discussion 98S-101S; quiz 106S-108S. PubMed ID: 16803418
    [Abstract] [Full Text] [Related]

  • 7. Immunomodulatory effects of HMG-CoA reductase inhibitors.
    Danesh FR, Anel RL, Zeng L, Lomasney J, Sahai A, Kanwar YS.
    Arch Immunol Ther Exp (Warsz); 2003 Jul 05; 51(3):139-48. PubMed ID: 12894868
    [Abstract] [Full Text] [Related]

  • 8. Statins: a treatment option for chronic heart failure?
    von Haehling S, Okonko DO, Anker SD.
    Heart Fail Monit; 2004 Jul 05; 4(3):90-7. PubMed ID: 15772704
    [Abstract] [Full Text] [Related]

  • 9. Statins and endothelial dysfunction.
    Larose E, Ganz P.
    Semin Vasc Med; 2004 Nov 05; 4(4):333-46. PubMed ID: 15861315
    [Abstract] [Full Text] [Related]

  • 10. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
    Comparato C, Altana C, Bellosta S, Baetta R, Paoletti R, Corsini A.
    Nutr Metab Cardiovasc Dis; 2001 Oct 05; 11(5):328-43. PubMed ID: 11887430
    [Abstract] [Full Text] [Related]

  • 11. [Statins and brain protection mechanisms].
    Tapia-Perez H, Sanchez-Aguilar M, Torres-Corzo J, Rodriguez-Leyva I, Herrera-Gonzalez LB.
    Rev Neurol; 2001 Oct 05; 45(6):359-64. PubMed ID: 17899518
    [Abstract] [Full Text] [Related]

  • 12. The effects of statins on endothelium, inflammation and cardioprotection.
    Elrod JW, Lefer DJ.
    Drug News Perspect; 2005 May 05; 18(4):229-36. PubMed ID: 16034478
    [Abstract] [Full Text] [Related]

  • 13. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation.
    Arnaud C, Mach F.
    Arch Mal Coeur Vaiss; 2005 Jun 05; 98(6):661-6. PubMed ID: 16007821
    [Abstract] [Full Text] [Related]

  • 14. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
    Fujita R, Matsushima T.
    Nihon Rinsho; 1999 Dec 05; 57(12):2821-5. PubMed ID: 10638219
    [Abstract] [Full Text] [Related]

  • 15. Microcirculation as a target for the anti-inflammatory properties of statins.
    Scalia R, Stalker TJ.
    Microcirculation; 2002 Dec 05; 9(6):431-42. PubMed ID: 12483541
    [Abstract] [Full Text] [Related]

  • 16. Potential vascular benefits of statins.
    Kinlay S.
    Am J Med; 2005 Dec 05; 118 Suppl 12A():62-7. PubMed ID: 16356810
    [Abstract] [Full Text] [Related]

  • 17. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
    Jantzen F, Könemann S, Wolff B, Barth S, Staudt A, Kroemer HK, Dahm JB, Felix SB, Landsberger M.
    J Physiol Pharmacol; 2007 Sep 05; 58(3):503-14. PubMed ID: 17928646
    [Abstract] [Full Text] [Related]

  • 18. Statins: multiple mechanisms of action in the ischemic brain.
    Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L.
    Neuroscientist; 2007 Jun 05; 13(3):208-13. PubMed ID: 17519364
    [Abstract] [Full Text] [Related]

  • 19. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS.
    Am J Cardiovasc Drugs; 2001 Jun 05; 1(6):411-20. PubMed ID: 14728000
    [Abstract] [Full Text] [Related]

  • 20. Statins and their role in vascular protection.
    Mason JC.
    Clin Sci (Lond); 2003 Sep 05; 105(3):251-66. PubMed ID: 12793855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.